Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in type 2 diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 4, 2006, Pages 307-312

  Tan, K C B ^a   Shiu, S W M ^a   Wong, Y ^a   Wong, W K ^b   Tam, S ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Apolipoprotein AI; Apolipoprotein E; Phospholipid transfer protein; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LIPOSOME; ORAL ANTIDIABETIC AGENT; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IN VIVO STUDY; INSULIN TREATMENT; LINEAR REGRESSION ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGULATORY MECHANISM; TRIACYLGLYCEROL BLOOD LEVEL; TURBIDIMETRY;

ADULT; APOLIPOPROTEINS E; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; REFERENCE VALUES; REGRESSION ANALYSIS;

EID: 33746081685     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.616     Document Type: Article

References (31)

1. Albers JJ, Cheung MC. Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr Opin Lipidol 2004; 15: 255-260.
2. Ehnholm S, van Dijk KW, van 't Hof B, et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res 1998; 39: 1248-1253.
3. van Haperen R, van Tol A, Vermeulen P et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20: 1082-1088.
4. Jiang XC, Bruce C, Mar J et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103: 907-914.
5. Desrumaux CM, Mak PA, Boisvert WA et al. Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells. J Lipid Res 2003; 44: 1453-1461.
6. Laffitte BA, Joseph SB, Chen M et al. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol Cell Biol 2003; 23: 2182-2191.
7. Yatsuya H, Tamakoshi K, Hattori H et al. Serum phospholipid transfer protein mass as a possible protective factor for coronary heart diseases. Circ J 2004; 68: 11-16.
8. Schlitt A, Bickel C, Thumma P et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 1857-1862.
9. Oka T, Kujiraoka T, Ito M et al. Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive. J Lipid Res 2000; 41: 1651-1657.
10. Huuskonen J, Ekstrom M, Tahvanainen E et al. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000; 151: 451-461,
11. Oka T, Kujiraoka T, Ito M et al. Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin Chem 2000;46:1357-1364.
12. Karkkainen M, Oka T, Olkkonen VM et al. Isolation and partial characterization of the inactive and active forms of human plasma phospholipid transfer protein (PLTP). J Biol Chem 2002; 277: 15 413-15 418.
13. Siggins S, Karkkainen M, Tenhunen J et al. Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J Lipid Res 2004; 45: 387-395.
14. Janis MT, Metso J, Lankinen H et al. Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem Biophys Res Commun 2005; 331: 333-340.
15. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 1998; 41: 929-934.
16. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP. Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in type 2 diabetic patients. Diabetes 1999; 48: 1631-1637.
17. Tan KC, Shiu SW, Wong Y. Plasma phospholipid transfer protein activity and small, dense LDL in type 2 diabetes mellitus. Eur J Clin Invest 2003; 33: 301-306.
18. Dullaart RP, De Vries R, Scheek L et al. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations. Scand J Clin Lab Invest 2004; 64: 205-215.
19. Huuskonen J, Olkkonen VM, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. Acyl chain and headgroup specificity of human plasma phospholipid transfer protein. Biochim Biophys Acta 1996; 1303: 207-214.
20. Korhonen A, Jauhiainen M, Ehnholm C, Kovanen PT, Ala-Korpela M. Remodeling of HDL by phospholipid transfer protein: demonstration of particle fusion by 1H NMR spectroscopy. Biochem Biophys Res Commun 1998; 249: 910-916.
21. Settasatian N, Duong M, Curtiss LK et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001; 276: 26 898-26 905.
22. Barter PJ, Rajaram OV, Chang LB et al. Isolation of a high-density-lipoprotein conversion factor from human plasma. A possible role of apolipoprotein A-IV as its activator. Biochern J 1988;254:179-184.
23. Pussinen PJ, Jauhiainen M, Metso J et al. Binding of phospholipid transfer protein (PLTP) to apolipoproteins A-I and A-II: location of a PLTP binding domain in the amino terminal region of apoA-I. J Lipid Res 1998; 39: 152-161.
24. Janis MT, Siggins S, Tahvanainen E et al. Active and low-active forms of serum phospholipid transfer protein in a normal Finnish population sample. J Lipid Res 2004; 45: 2303-2309.
25. Jauhiainen M, Ehnholm C. Determination of human plasma phospholipid transfer protein mass and activity. Methods 2005; 36: 97-101.
26. Desrumaux C, Athias A, Bessede G et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type Ila hyperlipidemic, type Ilb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999; 19: 266-275.
27. Schneider M, Verges B, Klein A et al. Alterations in plasma vitamin E distribution in type 2 diabetic patients with elevated plasma phospholipid transfer protein activity. Diabetes 2004; 53:2633-2639.
28. Oka T, Yamashita S, Kujiraoka T et al. Distribution of human plasma PLTP mass and activity in hypo- and hyperalphalipoproteinernia. J Lipid Res 2002; 43: 1236-1243.
29. Barlage S, Frohlich D, Boucher A et al. ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42: 281-290.
30. Pussinen PJ, Metso J, Malle E et al. The role of plasma phospholipid transfer protein (PLTP) in HDL remodeling in acute-phase patients. Biochim Biophys Acta 2001; 1533: 153-163.
31. Tan KC, Shiu SW, Wong Y, Tam S. Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005; 178: 365-370.